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A B S T R A C T   
Background: Transgender patients have unique healthcare needs, providing pharmacists with the opportunity to 
play an important role in transgender care through addressing the healthcare disparities observed in this patient 
group. 
Objective: This scoping review aimed to explore the role of pharmacists in transgender healthcare. 
Methods: Six databases were searched from inception: Emcare, Informit, MEDLINE (Ovid), PubMed, Scopus, and 
Web of Science. The first author performed screening and data extraction in consensus with co-authors. Preferred 
Reporting Items for Systematic reviews and Meta-Analysis extension for Scoping Reviews (PRISMA-ScR) was 
utilised to report this review. Themes related to the role of pharmacists in transgender healthcare were identified. 
Results: A total of 356 studies were identified; however, only 15 studies, all from the USA met the selection 
criteria and were included in this review. Study types included empirical research, practice reports and opinion 
pieces such as commentaries, editorials, and reports. Pharmacists were found to practise in two different care 
settings: community and interdisciplinary clinics, performing various roles in transgender healthcare, including 
patient education and counselling, management of cross-sex hormonal therapy, patient advocacy and provision 
of preventative care. They were also responsible for the provision of culturally sensitive care in an inclusive and 
welcoming environment. Although pharmacists considered their role important, they lacked confidence in their 
knowledge to provide appropriate care to this patient group. 
Conclusion: This review has highlighted that there is a need for education in transgender care for both phar-
macists and pharmacy students, so that they are both confident and comfortable to play a meaningful role in 
transgender care. Pharmacists’ involvement in addressing the health disparities experienced will contribute to 
improving the overall health outcomes for this group.   
Introduction 
The term transgender (TG) is an umbrella term that encompasses 
individuals whose gender identity differs from their biological sex.1 In 
this review, the term TG refers to persons that identify as trans, trans-
men, transwomen, genderqueer, agender, gender fluid, non-binary, 
sistergirl or brotherboy. Although the exact numbers of the TG popu-
lation are not available, it is estimated that approximately 0.1–2% of the 
population worldwide identifies as TG.2 With increasing social accep-
tance, many TG patients are accessing care for gender affirmation and 
other health issues.3 
TG patients have diverse healthcare needs.4 The prevalence of 
mental health issues such as depression, anxiety and suicidal ideation is 
significantly higher compared to the general population.5–8 A recent 
survey reported that approximately 56% of TG patients were diagnosed 
with depression, and 40% with anxiety.5 These patients are also more 
likely to engage in high-risk behaviours such as tobacco, alcohol and 
substance abuse, unprotected sex and needle sharing.6,9 The risk of 
developing HIV infection in TG women is 49 times higher than the 
general population.10 Approximately 78% of TG people desire hormonal 
treatment for gender affirmation; however, only 50% of them receive 
this therapy.6 It has been reported that between 23 and 71% of TG 
women procure hormones from a non-medical source and may use 
higher than the recommended dosage.11–14 Although TG patients have 
these unique healthcare needs, some may be hesitant to access required 
care based on their previous experiences of discrimination and mar-
ginalisation emanating from the healthcare system.4,8,15 Many TG pa-
tients have reported that healthcare providers lack knowledge about TG 
care and in many instances, find themselves teaching these providers 
about TG care.7,16 A recent Australian survey of TG patients highlighted 
the need for improved access to healthcare and better training for 
healthcare professionals.4 
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Pharmacists, being highly accessible and trusted health pro-
fessionals, may improve health outcomes for TG patients through their 
expert knowledge of healthcare issues and in collaboration with other 
healthcare professionals.6,17,18 This aligns with the Pharmaceutical So-
ciety of Australia (PSA) Competency Standards for Pharmacists that 
states pharmacists should collaborate and deliver culturally responsive, 
patient-centred care and promote the judicious use of medications for all 
patients.19 In addition, the Accreditation Standards for Pharmacy Pro-
grams in Australia and New Zealand require all pharmacy education 
programs to promote inclusive and responsive patient-centred care that 
respects cultural diversity and assures the safety of every patient.20 The 
increasing demand for TG care6 informed the aim of this review; to 
identify the pharmacists’ role, any barriers to care provision and 
training requirements for providing this care. 
Method 
This scoping review was conducted in accordance with the Preferred 
Reporting Items for Systematic reviews and Meta-Analysis extension for 
Scoping Reviews (PRISMA-ScR).21 
Search strategy 
A comprehensive search of the literature from inception to June 15, 
2020, was performed using the following electronic databases: Emcare, 
Informit, MEDLINE (Ovid), PubMed, Scopus, and Web of Science. The 
searches were conducted using terms such as transsexual* OR trans-
gender*, two spirit persons, two-spirit person, two-spirit persons, 
bigender people, trans persons, gender identity disorder, gender 
dysphoria, pharmacist, pharm*, education, and health care. The details 
of the search strategy used for MEDLINE (Ovid) database are included in 
Appendix 1. Additional articles were located through hand searching of 
the reference lists of the retrieved articles. 
Inclusion and exclusion criteria 
Articles were included if they described an interaction between 
pharmacists and TG patients or identified the need for pharmacist 
training in TG health care or described hormonal or other gender 
affirmation treatment regime for the TG patient. Original research, 
practice reports, and opinion pieces such as commentaries, editorials 
and reports in full text and English were included. Review articles or the 
articles not related to the pharmacist or pharmacy involvement in 
transgender healthcare or evaluating transgender health care training 
provided to student pharmacists were excluded. 
Extraction and analysis 
Fig. 1 illustrates the process of study selection for this review. The 
selected articles were imported in the EndNote software, and duplicates 
were removed. First, the titles, abstracts and full texts of the studies were 
screened by the first author. Then, the co-authors independently 
assessed the study selection. Any disagreements regarding study selec-
tion were resolved through consensus among the authors. 
The data from the included studies were charted into a table format 
recording the author, year of publication, place of publication, study 
design, participants (if applicable), setting, aims, and key findings. The 
first author charted the data, and the co-authors independently reviewed 
the results. The data charting form was updated regularly with the in-
formation as a result of this iterative process. 
A descriptive analysis was applied to identify the extent, nature and 
distribution of the included records.22 Additionally, thematic synthesis 
was conducted by all authors to identify the themes related to the role of 
a pharmacist in TG healthcare. A quality assessment of the included 
studies was not performed as this scoping review aimed to identify all 
relevant literature regarding the role of pharmacists in TG health care. 
Fig. 1. Flowchart for study selection for the scoping review.  
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Results 
A total of 15 studies describing interactions of pharmacists with TG 
patients were included in this scoping review. A variety of study types 
were found including empirical research23–28 (n = 6, 40%), practice 
reports29–31 (n = 3, 20%), commentaries32–34 (n = 3, 20%), edito-
rials35,36 (n = 2, 13%), and reports with opinions37 (n = 1, 7%). All 
studies (n = 15, 100%) originated in the United States of America (USA), 
with no studies from any other country, including Australia, identified. 
The publication dates ranged between the years 2016 and 2019, with 
most of the studies published in the years 201729,30,33–35 (n = 5, 30%) 
and 201923,24,26–28,31,37 (n = 8, 53%). 
Three studies23,25,27 investigated attitudes, perceptions and knowl-
edge of community pharmacists in the provision of TG care. Three 
studies29–31 described the role of a pharmacist in an interdisciplinary 
healthcare model, while only two studies26,27 out of the six empirical 
studies, evaluated perceptions of TG patients towards receiving care 
from pharmacists. Another study identified perceptions of LGBTQIA 
patients towards influenza vaccine uptake from various settings, 
including pharmacy.28 Additionally, one study24 reported the views of 
TG patients along with other patients receiving pre-exposure prophy-
laxis (PrEP) in a pharmacist-led PrEP program. 
Eight themes were identified relating to the role of pharmacists in TG 
healthcare (see Table 1). The most common themes were the need for 
additional education for pharmacists in TG healthcare23,25–27,33–37 (n =
9, 60%), the role of pharmacists in TG patient education and 
counselling24,26,27,29,31,32,34,35 (n = 8, 53%) and management of 
cross-sex hormone therapy (CSHT)27,29,30,32–35(n = 7, 47%). 
Patient education and counselling 
Patient education and counselling was one of the most highlighted 
roles of the pharmacist in the provision of TG health 
care.24,26,27,29,31,32,34,35 Pharmacists were reported to counsel patients 
on their hormonal medications26,27,29,32,34,35 and PrEP medications24,31 
in over 50% of the studies. 
Management of CSHT 
Seven studies27,29,30,32–35 reported the role of pharmacists in the 
management of CSHT with six including education and 
counselling.26,27,29,32,34,35 In this role, pharmacists conducted medica-
tion reviews,27,29,30,33 obtained patient consent for CSHT treatment,29,30 
advised TG patients regarding the changes in fertility due to CSHT and 
encouraged them to consider family planning options before initiation of 
CSHT.30,34 Additionally, pharmacists performed other roles such as 
individualising treatment plans,32,33,35 calculating creatinine clear-
ance,33 designing the dosing regimen for TG patients, suggesting 
appropriate formulations based on patient factors,30 as well as collab-
orating with other health professionals to improve the outcomes of the 
CSHT.30,32,33,35 
Patient advocacy 
Six studies24,26,30,33–35 identified pharmacists as advocates for TG 
patients as they assisted in getting pre-approvals for medications 
through government and company patient assistance programs.24,26,33 
Other examples of advocacy included pharmacists acquiring medica-
tions24,26,33 and assisting TG patients in submitting their insurance 
claims.30,33,34 Pharmacists also provided referrals to other medical and 
psychosocial services.24,30,35 
Preventative healthcare 
Many studies reported the role of pharmacists in the provision of 
preventative healthcare for TG patients.24,31–35 Pharmacists performed 
screenings for STIs and HIV,24,31,34,35 mental health,29,34 and cardio-
vascular health.32,33 In one study, pharmacists conducted medication 
reviews, provided PrEP to eligible patients, and provided education on 
PrEP.24 Moreover, three studies28,33,34 recorded pharmacists immu-
nizing for vaccine-preventable diseases. Pharmacists also assisted in 
smoking cessation27,29,32 and prevention and management of alcohol or 
substance abuse.29 Two studies30,32 identified the role of pharmacists in 
the provision of lifestyle advice such as diet, exercise, and weight 
management for TG patients. 
Provision of culturally sensitive care and inclusive environments 
Five studies specified that pharmacists have a responsibility to pro-
vide culturally sensitive care to their TG patients.26,27,33,34,37 Pharma-
cists and pharmacy staff should ask for preferred name, gender identity 
and preferred pronouns to avoid misgendering TG patients.37 Also, the 
provision of an inclusive environment for LGBT/TG patients was rec-
ognised as the responsibility of the pharmacist.26,33–35,37 It was sug-
gested that pharmacists should update their healthcare policies, train 
staff, display materials and signs for TG/LGBT patient inclusivity, and 
where possible, incorporate gender-neutral restrooms to create a 
welcoming environment for this patient group.26,27,33,34,37 
Barriers to TG care 
Six studies23,25–27,33,37 identified various barriers to the provision of 
TG care, from both a pharmacist and patient perspective as listed in 
Table 2. 
The need for additional education 
Nine studies23,25–27,33–37 reported the need for additional training for 
pharmacists in TG healthcare to provide appropriate care for this pop-
ulation. Additional training may be integrated into pharmacy curricu-
lum23,27,33–37 and/or delivered as a part of continuing education 
(CE).23,27,35,37 
Undertake research 
Two studies33,35 suggested that pharmacists should contribute to 
transgender care research. The research could be undertaken to estab-
lish safety and efficacy of the existing and new treatment protocols for 
gender affirmation treatment. Optimising the implementation of phar-
macy based preventative care services to improve TG health outcomes 
also needs to be investigated. 
Discussion 
This review was undertaken to map the role of pharmacists in TG 
healthcare. The 15 articles identified have relied only on US data, 
underlining a lack of studies from other countries, including Australia. 
Pharmacists have been reported to play a significant role in TG 
healthcare and the role included patient education and 
counselling,24,26,27,29,31,32,34,35 management of CSHT,27,29,30,32–35 and 
provision of preventative care services.24,31–35 Pharmacists have pro-
vided culturally sensitive care in an inclusive environment for TG/LGBT 
patients,26,27,33,34,37 also in some instances advocating for their TG pa-
tients for affordable healthcare services.24,26,30,33–35 Pharmacists are 
therefore well positioned to undertake research to establish safety and 
efficacy of available treatment protocols.33,35 Barriers have been put 
forward to the provision of TG care in pharmacy settings such as stigma, 
discrimination, and verbal or physical abuse.23,25–27,33,37 Although most 
of the pharmacists23,25,27 and TG patients26,27 believed that pharmacists 
play an important role in TG healthcare, both groups reported a signif-
icant gap in pharmacists’ knowledge of TG healthcare. Importantly over 
the half of articles23,25–27,33–37 indicated the need for TG healthcare 
education for pharmacists and pharmacy students. 
Pharmacists are reported to educate and counsel TG patients across 
various areas of healthcare.6,9,17,18 However, the practicality of the 
provision of advice in the community pharmacy settings needs to be 
explored. Many pharmacies lack the availability of private spaces for all 
patient consultation and often use the pharmacy counter for 
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Table 1 





Study design, Participants and Setting Aim Main findings Themes 
Empirical studies 
Aragon et al.,23 
2019, USA 
Quantitative: Survey; 
Pharmacists (n = 342); Community 
Pharmacy 
To determine whether community 
pharmacists in North Carolina have 
personal confidence, comfort level, and 
resources needed to provide TG care 
Received TG care education at university: 
3%; Received continuing education (CE): 
12%; Unaware of current practice 
guidelines: 89%; Pharmacists’ role is 
important in TG care: 71%; Comfortable in 
welcoming TG patients to their pharmacy: 
66%; Barriers to the provision of TG care: 
Negative views of the pharmacists towards 
TG patients; Low comfort in the provision of 
TG care 
Need for additional 
education in TG 
healthcare 
Barriers to the 
provision of TG care 
Haven et al.a,24 
2019, USA 
Quantitative: Survey; 
Pharmacists (n = 7) and PrEP patients 
(including TG patients) (n = 60); 
University-based HIV clinic, community 
pharmacy, and community-based units 
To investigate the acceptability and 
feasibility of a pharmacist-led HIV 
screening and PrEP (P-PrEP) for individuals 
at risk for HIV acquisition 
Role of the pharmacist: Taking medical 
history patient, HIV risk assessment; PrEP 
counselling; Baseline laboratory testing; 
HIV and STI screening; Authorising 
emtricitabine/tenofovir disoproxil 
fumarate (F/TDF) prescriptions to eligible 
patients; Assessing adherence to F/TDF 
Patient response to pharmacist service: ease 
of PrEP care, quick service, and friendly and 
honest pharmacist 
Pharmacists’ response: comfortable in 
point-of-care testing, rarely uncomfortable 
(2%) conducting sexual histories or 





Leach et al.,25 
2016, USA 
Quantitative: Online survey, cross- 
sectional; 
Pharmacists (n = 63); Community 
pharmacy 
To measure the general perceptions and 
attitudes of community pharmacy residents 
towards TG patients and health; to identify 
gaps in didactic education regarding TG 
healthcare among residents, and to 
evaluate residents’ level of support for 
pharmacists receiving education in 
transgender health 
Did not receive TG care education at 
university: 71%; 
TG health should be integrated into 
pharmacy curricula: 68%; TG health should 
be integrated into CE programs: 78%; 
Pharmacists’ role is important in TG care: 
83%; Confident in treating TG patients: 
36%; Need for more education in TG health: 
73%; Barriers to the provision of TG care: 
Discrimination; Lack of provider knowledge 
Need for additional 
education in TG 
healthcare 
Barriers to the 
provision of TG care 







Lewis et al.,26 
2019, USA 
Quantitative: Survey; 
Transgender and gender-nonconforming 
patients (TGNC) (n = 316); Community 
To evaluate TGNC adults’ worries and 
coping actions related to discrimination by 
healthcare professionals 
Accessed pharmacy services: 86%; 
Worrying about the discrimination, while 
accessing pharmacy services: 41.6%; 
Pharmacists have very little or no 
competency in the provision of TG care: 
52%; Avoided care due to past 
embarrassment at pharmacies: 13%; 
Avoided care due to medication cost: 38% 
Coping actions: choosing providers known 
to be gender-affirming, delay medical care, 
not disclosing their authentic gender 
identity, use of natural products to avoid 
obtaining a prescription, ask friends or 
family members to fill their prescriptions, 
and obtain products from online 
pharmacies not requiring a prescription 
Need for additional 
education in TG 
healthcare 
Barriers to the 
provision of TG care 







Melin et al.,27 
2019, USA 
Quantitative: Survey; Descriptive, cross- 
sectional; Pharmacists (n = 96) and TG 
patients (n = 31); Community 
To assess pharmacist readiness to provide 
transgender care through measuring both 
pharmacists’ knowledge and attitudes 
towards transgender patients; to assess 
transgender patients’ perception of 
pharmacist readiness to provide them 
pharmaceutical care 
Pharmacists survey: Knowledge scores in 
the low and moderate ranges: 90%; 
Pharmacists’ role is important in TG care: 
96%; Comfortable in suggesting treatment 
options to TG patients: 22%; Barriers to the 
provision of TG care: stigma (84%), verbal 
rejection (17%), violence (5%) 
TG patient survey: Pharmacists’ role is 
important in TG care: 87%; Comfortable 
with the pharmacist while receiving 
services: 66%; Barriers to the provision of 
TG care: stigma (60%), discrimination 
(63%), verbal rejection (50%), lack of 
knowledge by health care providers (70%); 
Pharmacist’s role in TG care: Medication 
review (71%), hormonal treatment 
counselling (65%), medical conditions and 
Need for additional 
education in TG care 
Barriers to the 
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Study design, Participants and Setting Aim Main findings Themes 
nonhormonal treatment counselling (52%), 
and education on adverse effects and their 
management (68%) 
Padilla et al.a,28 
2019, USA 
Quantitative: A prospective survey; 
The members of the Hispanic LGBTQIA 
community (n = 126); Community 
To identify factors that influence 
behaviours, attitudes, and perceptions 
toward the uptake of the influenza vaccine 
within the Hispanic LGBTQIA community 
27% of the participants reported that their 




Kaigle et al.,29 
2017, USA 
Practice report; Veteran TG patients, 
interdisciplinary team consists of 
endocrinologist, primary care provider, 
clinical pharmacist, psychologist, and 
social worker; TG healthcare clinic 
To report the development and 
implementation of the Transgender 
Healthcare Clinic model with 
interprofessional collaboration 
Role of the pharmacist: Patient education 
and obtain patient consent to treatment 
with CSHT; Identify potential drug 
interactions; Before initiation of the CSHT 
identify and address contraindications, 
precautions, and medical risk factors. 
Psychiatric pharmacist: address issues such 
as substance abuse, tobacco abuse, multiple 
mental health diagnoses, and suicidal 







et al.,30 2017, 
USA 
Practice report; Pharmacist in an 
interprofessional team; TG healthcare 
clinic 
To describe the role of a pharmacist in the 
provision of care to TGNC patients in a 
medical home model of care 
Role of the pharmacist: Patient education 
and obtain patient consent to treatment 
with cross-sex hormone therapy; Discuss 
different formulations for CSHT and select 
the most suitable formulation for an 
individual patient; Provide advice on 
smoking cessation, weight management 
and a healthy lifestyle; Contact insurance 
companies for coverage of CSHT costs; 









Ryan et al.a,31 
2019, USA 
Practice report; Pharmacist Clinician 
(PhC) and Patients living with HIV or 
high-risk patients including TG patients; 
Interprofessional and PhC-run clinics 
To describe how the pharmacist clinicians 
were integrated into an innovative 
pharmacy practice model that provided 
care to patients living with or at risk of 
acquiring HIV and/or hepatitis C virus 
(HCV) infection. 
Role of the pharmacist: Improve patient 
adherence to antiretroviral therapy (ART); 
patient education; order necessary 
laboratory tests, initiate ART; evaluate ART 
regimens for appropriateness; select 
appropriate dosage form; check drug-drug 
interactions; communicate possible adverse 
effects and their management; check for 
need of additional antibiotic prophylaxis; 






Bass et al.,32 
2018, USA 
Commentary Description of CSHT for nonbinary 
patients’, and the role of the pharmacist in 
providing care to this group 
Role of the pharmacist: Individualise 
dosing regimen of CSHT and provide 
alternatives to attain patient’s goal of the 
therapy; Patient education on CSHT; 
recommend appropriate dosage form 
considering pharmacodynamic and 
pharmacokinetic properties of the 
medication; Management of potential 
cardiac and thromboembolic risk factors; 
monitor glucose, lipid, and haematocrit 
levels and provide counselling on diet, 








Commentary Description of the role of the pharmacist in 
TG healthcare 
Foundation elements to provide TG care: 
Pharmacist education to improve 
knowledge of available gender-affirmation 
therapies; Cultural competency training for 
pharmacists to improve TG patient 
interactions 
Role of the pharmacist: Individualise 
treatment regimens of CSHT and monitor 
medication safety; Monitor parameters 
such as blood pressure, weight, pulse and 
provide information on prevention of deep 
vein thrombosis prevention strategies; 
Calculation of creatinine clearance 
considering muscle mass and hormone 
therapy of TG patient; Provide a welcoming 
environment to TG patients and use correct 
pronouns; Immunisations; Improve 
medication access; Contribute to TG 
healthcare research 
Need for additional 
education in TG 
healthcare 
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counselling.38 Moreover, some pharmacists have been hesitant in 
providing private spaces due to the time constraints, lack of floor space 
and the costs of employing another pharmacist to oversee dispensing 
and other pharmacy operations.38 Even though generally TG patients 
feel safer in discussing their healthcare issues with pharmacists than 
physicians,6 lack of privacy may lead to non-disclosure of their authentic 
gender identity.33 This could impact the pharmacist’s recommendations 
regarding medications and other preventative care services. Further-
more, the inclusion of pharmacists in interprofessional teams at TG 
clinics for providing comprehensive clinical counselling on gender 
affirmation therapies and other preventative measures, should be 
considered to ameliorate the pressures of time on the community 
pharmacists. 
Although pharmacists’ role has expanded beyond the dispensary, the 
remuneration for their time, expertise and skills for offering professional 
services need to be considered. Inadequate or no remuneration for these 
services may limit their delivery through pharmacies.39 The 
fee-for-service model may be introduced to improve the pharmacists’ 
willingness for offering professional services.39 In Australia, this could 
be addressed by pharmacists being granted access to allied health 
Medicare Benefits Schedule (MBS) items for claiming the professional 
services offered to their patients.40 Adequate remuneration may facili-
tate the provision of healthcare services through community pharmacies 
that may improve the overall health outcomes of TG patients. 
Even though pharmacists are providing healthcare to TG patients 
across a range of areas, few studies have evaluated their attitudes, 





Study design, Participants and Setting Aim Main findings Themes 
Maxwell 
et al.,34 2017 
To identify the role of a pharmacist in LGBT 
health, recognise specific concerns with 
mental and sexual health, describe gender- 
transitioning pharmacotherapy, and 
discuss the current stance of LGBT health in 
pharmacy education 
Need for the addition of LGBT health into 
the curricula 
Role of the pharmacist: Mental health 
screening; Sexual health: Encourage routine 
vaccinations including hep B and hep C 
vaccines; Provide STIs and HIV screening; 
Recognise and refer for appropriate cancer 
screening; Provide birth control advice; 
Patient education on CSHT; Collaborate 
with other health professionals to attain 
treatment goals; Individualise dosing 
regimens; Assist with insurance claims; 
Provide culturally sensitive care; Provide an 
inclusive environment for the LGBT 
population 
Need for additional 

















Editorial Community-based pharmacy residency: At 
the forefront of improving health care 
Pharmacists have an important role in the 
provision of TG care. Integration of TG 
healthcare training into pharmacy 
curriculum may be required. 
Need for additional 




Editorial Pharmacists’ role in the provision of TG 
healthcare 
Community pharmacists require training in 
TG health, and there is a need for the 
addition of TGNC health in pharmacy 
curricula. 
Role of the pharmacist: Provide TG- 
inclusive and welcoming environments; 
Interprofessional collaboration in medical 
care models; CSHT: Patient education and 
individualise treatment plan; Provide 
preventative services such as 
immunisations, HIV screening; refer TG 
patients to medical and psychosocial 
services, if needed; Contribute to research 
in TG healthcare 
Need for additional 
education in TG 
healthcare 













Report Providing healthcare to TG patients Barriers to the provision of TG care: 
TG patient barriers: Financial challenges; 
Unemployment; Fear of discrimination; 
High prevalence of healthcare issues such 
as mental health issues, suicide rates 
Pharmacy barriers: Inappropriate or 
incomplete electronic medical and 
pharmacy records for gender identity, legal 
sex and birth sex; Discrimination; Denial of 
care due to personal or religious beliefs of 
the pharmacist; Minimal or no education on 
TG health 
Pharmacies should provide inclusive and 
welcoming environments for TG patients. 
Pharmacy staff should use appropriate 
terminology to provide culturally sensitive 
care. 
Need for additional 
education in TG 
healthcare 
Barriers to the 
provision of TG care 







Total studies n = 15     
a Study participants included cisgender and TG patients. The study outcomes were described together for all patient groups and were not specifically reported for the 
TG patient population. CSHT= Cross-sex hormone therapy, TG = transgender, TGNC = transgender and gender-nonconforming, LGBTQIA = Lesbian, gay, bisexual and 
transgender, queer, intersex and asexual. 
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knowledge and skills in the provision of such care.23,25,27 It has been 
reported that TG patients have experienced denial of healthcare services 
due to pharmacists’ negative attitudes and lack of knowledge of TG 
healthcare issues.15 However, only two studies explored perceptions of 
TG patients about towards the provision of care by pharmacists.26,27 
Such studies may be important not only to provide insights about the 
expectations TG patients have of their pharmacists, but also to design 
appropriate education in TG healthcare for pharmacists. Some educa-
tional interventions have improved attitudes of pharmacy students to-
wards TG patients and therapeutic knowledge of TG healthcare.11,41,42 
Knowledge of current guidelines and other practice resources in TG care 
that assist when providing gender affirming care and appropriate pre-
ventative care for these patients, could be improved. These findings 
suggest a need to develop and deliver TG healthcare continuing edu-
cation for pharmacists to improve their therapeutic knowledge for 
adequate provision of care for their TG patients. Additionally, integra-
tion of such training into the pharmacy curricula to improve knowledge, 
cultural competence and confidence of future pharmacists in addressing 
TG healthcare needs, would be beneficial. 
Many TG patients consider healthcare provider knowledge of TG 
issues along with their cultural awareness as important factors while 
accessing care.15,26 Misgendering or inappropriate use of pronouns in 
the pharmacy setting have deterred some TG patients from accessing 
care.26 Australia as with many other countries is a multicultural society 
and as such pharmacists have to deal with the requirements of different 
ethnic, religious and social groups.43 Increased workload and lack of 
knowledge of certain cultures may inadvertently result in culturally 
inappropriate delivery of pharmacist services. However, with an 
awareness of cultural diversity, pharmacists unsure about approaching 
TG patient may be advised to use gender-neutral language.6 Addition-
ally, it is recommended that pharmacists acknowledge that the provision 
of an inclusive and welcoming environment is paramount for the de-
livery of culturally sensitive care to TG patients.6 Therefore, cultural 
competency training for pharmacists and pharmacy staff providing TG 
care is necessary to address cultural barriers and may assist in devel-
oping trusted relationships with these patients. 
Many TG patients have financial difficulties and do not have private 
insurance.6,15 Medication cost is one of the barriers to accessing care.6 In 
Australia, not all medications for the gender affirmation treatment are 
subsidised through the Pharmaceutical Benefits Scheme.2 Thus, being an 
advocate for TG patients and assisting them in navigating the healthcare 
system for affordable care is crucial for improving their healthcare 
outcomes.6,33 
The current practice guidelines for gender affirmation care are based 
on the clinical experience and not randomised clinical trials.2,33,35,44,45 
Pharmacists need to undertake research to establish the optimal dosing 
regimens of CSHT, pharmacodynamic and pharmacokinetic factors 
affecting the individual response to the therapy, drug-drug interactions, 
drug interactions with food and complementary medicines.33,35 Also, 
research is required to establish how the preventative healthcare ser-
vices offered through community pharmacies may improve the overall 
well-being of TG patients.33 
Future research 
This review has identified that pharmacists require additional 
training in TG healthcare to bridge the gap in their pharmacotherapeutic 
knowledge and gain cultural competency. Future studies are necessary 
to address the impact of such training on the attitudes, knowledge and 
practice of pharmacists in the provision of TG healthcare. In addition, 
more studies are required to evaluate the perceptions of TG patients 
about pharmacists’ role in their healthcare. 
Limitations 
This review may have some limitations. Although a comprehensive 
search strategy was applied to locate relevant literature, some articles 
may have been excluded if they were not published in the English lan-
guage or if they were not listed in the searched databases. 
Conclusion 
This review indicates that the role pharmacists may play in TG 
healthcare is both complex and varied. Highlighted is the need for 
additional TG healthcare education in therapeutics as well as cultural 
sensitivity for pharmacists and pharmacy students. Such training would 
assist in delivering culturally responsive and patient-centred care as is 
envisaged by the Pharmaceutical Society of Australia’s competency 
standards.19 TG healthcare education and training can be integrated into 
pharmacy curricula and continuing education programs to improve 
confidence and comfort levels of pharmacists and pharmacy students in 
the provision of such care, with a view to improving health outcomes for 
this patient group. 
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Appendix 1. Search strategy for MEDLINE (Ovid) 
1. Transgender persons/ 
2. Pharmacists/ 
3.1 and 2. 
4. Exp Education/ 
5.3 and 4. 
6. Exp “Delivery of Health Care”/ 
7.3 and 6. 
8. Pharmacies/ 
Table 2 
Pharmacists and patient barriers to the provision of TG healthcare.  
Pharmacist barriers Patient barriers 
Negative attitudes towards TG patients23 
Low comfort in the provision of such 
care23 





Violence including physical harm27,33 
Inappropriate or incomplete electronic 
medical and pharmacy records for 
gender identity, legal sex and birth 
sex37 
Denial of care due to pharmacist’s 
personal or religious beliefs33,37 
High unemployment rates33,37 
Financial challenges33,37 
Fear of discrimination27,33 
Past experiences of accessing healthcare 
from the pharmacy26 
Fear of pharmacy staff causing physical 
harm or questioning the legitimacy of 
the prescription or denying medication 
supply or accusing of fraud due to legal 
documents not reflecting their physical 
appearance26,33  
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9.1 and 4 and 8. 
10.1 and 6 and 8. 
11. Gender Dysphoria/ 
12.3 and 11. 
13. Transsexualism/ 
14.3 and 13. 
15. Gender identity disorder.mp. 
16.3 and 17. 
Appendix 2. Terminology  
Term Definition 
Trans or transgender A person whose gender identity differs from their biological sex 
Transman A person with a male gender identity and female-assigned birth sex 
Transwoman A person with a female gender identity and a male assigned birth sex 
Genderqueer or gender nonconforming A person who identifies as not exclusively masculine or feminine 
Agender A person who identifies as genderless or gender neutral 
Gender fluid A person whose gender identity fluctuates 
Non-binary A person who does identifies as neither a male nor a female 
Brotherboy Aboriginal and Torres Strait Islander people may use this term for a person with a male spirit and female sex assigned at birth 
Sistergirl Aboriginal and Torres Strait Islander people may use this term for a person with a female spirit and male sex assigned at birth  
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